☰

Hermela Shimelis, Ph.D. - Publications

Affiliations: 
2013 Toxicology University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Molecular Biology, Cell Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Hu C, Belur Nagaraj A, Shimelis H, Montalban G, Lee KY, Huang H, Lumby CA, Na J, Susswein LR, Roberts ME, Marshall ML, Hiraki S, LaDuca H, Chao E, Yussuf A, et al. Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C. Cancer Research. PMID 37253112 DOI: 10.1158/0008-5472.CAN-22-2319  0.366
2022 Deshmukh D, Xu J, Yang X, Shimelis H, Fang S, Qiu Y. Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6. Pharmaceutics. 14. PMID 35456636 DOI: 10.3390/pharmaceutics14040802  0.479
2022 Minguillón J, Ramírez MJ, Rovirosa L, Bustamante-Madrid P, Camps-Fajol C, Ruiz de Garibay G, Shimelis H, Montanuy H, Pujol R, Hernandez G, Bogliolo M, Castillo P, Soucy P, Martrat G, Gómez A, et al. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. Cancers. 14. PMID 35053516 DOI: 10.3390/cancers14020353  0.32
2020 Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. Journal of the National Cancer Institute. PMID 32091585 DOI: 10.1093/Jnci/Djaa023  0.463
2019 Li H, LaDuca H, Pesaran T, Chao EC, Dolinsky JS, Parsons M, Spurdle AB, Polley EC, Shimelis H, Hart SN, Hu C, Couch FJ, Goldgar DE. Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31853058 DOI: 10.1038/S41436-019-0729-1  0.384
2019 Yadav S, LaDuca H, Polley E, Shimelis H, Niguidula N, Hu C, Lilyquist J, Na J, Lee K, Gutierrez S, Yussuf A, Hart S, Davis BT, Chao E, Pesaran T, et al. Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer patients. Journal of Clinical Oncology. 37: 1514-1514. DOI: 10.1200/Jco.2019.37.15_Suppl.1514  0.452
2018 Hu C, LaDuca H, Shimelis H, Polley EC, Lilyquist J, Hart SN, Na J, Thomas A, Lee KY, Davis BT, Black MH, Pesaran T, Goldgar DE, Dolinsky JS, Couch FJ. Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes. Jco Precision Oncology. 2. PMID 31497750 DOI: 10.1200/PO.17.00291  0.377
2018 Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, Doonanco K, Foreman AK, Ritter DI, Jimenez S, Trapp M, Offit K, Plon SE, Couch FJ. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 30504931 DOI: 10.1038/S41436-018-0361-5  0.424
2018 Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute. PMID 30099541 DOI: 10.1093/Jnci/Djy106  0.484
2018 Antwi SO, Fagan SE, Chaffee KG, Bamlet WR, Hu C, Polley EC, Hart SN, Shimelis H, Lilyquist J, Gnanaolivu RD, McWilliams RR, Oberg AL, Couch FJ, Petersen GM. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Journal of the National Cancer Institute. PMID 29982661 DOI: 10.1093/Jnci/Djx272  0.445
2018 Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Jama. 319: 2401-2409. PMID 29922827 DOI: 10.1001/Jama.2018.6228  0.449
2018 Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017772285. PMID 29791287 DOI: 10.1200/Jco.2017.77.2285  0.316
2018 Couch F, Shimelis H, Dolinsky JS, Polley E, Horton C, Yussuf A, Hoang L, Lilyquist J, Speare V, Hu C, Hart S, LaDuca H. Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes. Journal of Clinical Oncology. 36: 1524-1524. DOI: 10.1200/Jco.2018.36.15_Suppl.1524  0.459
2018 Couch F, Shimelis H, LaDuca H, Hu C, Hart S, Polley E, Pesaran T, Tippin-Davis B, Goldgar D, Dolinsky J. Abstract PD1-01: Triple negative breast cancer predisposition genes Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-01  0.486
2018 Couch F, Shimelis H, Hart S, Moore R, Thomas A, Lipton G, Iversen E. Abstract GS4-06: Cancer risks and response to targeted therapy associated with BRCA2 variants of uncertain significance Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs4-06  0.461
2017 Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, ... ... Shimelis H, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics. PMID 29058716 DOI: 10.1038/Ng.3785  0.441
2017 Lilyquist J, LaDuca H, Polley E, Davis BT, Shimelis H, Hu C, Hart SN, Dolinsky JS, Couch FJ, Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecologic Oncology. PMID 28888541 DOI: 10.1016/J.Ygyno.2017.08.030  0.421
2017 Pelttari LM, Shimelis H, Toiminen H, Kvist A, Törngren T, Borg Å, Blomqvist C, Bützow R, Couch F, Aittomäki K, Nevanlinna H. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication. Clinical Genetics. PMID 28802053 DOI: 10.1111/Cge.13123  0.443
2017 Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Jama Oncology. PMID 28418444 DOI: 10.1001/Jamaoncol.2017.0424  0.486
2017 Shimelis H, Mesman RL, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja FM, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomaki K, Andrulis IL, et al. BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Research. PMID 28283652 DOI: 10.1158/0008-5472.Can-16-2568  0.419
2017 Couch F, Hu C, Lilyquist J, Shimelis H, Akinhanmi M, Na J, Polley E, Hart S, McFarland R, LaDuca H, Huether R, Goldgar D, Dolinsky J. Abstract S2-01: Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S2-01  0.485
2017 Couch F, Lilyquist J, Na J, Hu C, Polley E, Shimelis H, Akinhanmi M, McFarland R, LaDuca H, Goldgar D, Dolinsky J. Abstract P5-09-03: Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-09-03  0.488
2017 LaDuca H, Hu C, Shimelis H, Polley E, Lilyquist J, Black MH, Davis BT, Goldgar DE, Dolinsky J, Couch FJ. Abstract 4286: What have we learned from pancreatic cancer patients undergoing multigene panel testing Epidemiology. 77: 4286-4286. DOI: 10.1158/1538-7445.Am2017-4286  0.336
2017 Chao EC, Pritzlaff M, Pia S, McFarland R, Li S, Dolinsky J, Goldgar D, Shimelis H, Couch F, Holly L. Abstract 3406: Hereditary risks of male breast cancer in a multi-gene panel testing cohort Cancer Research. 77: 3406-3406. DOI: 10.1158/1538-7445.Am2017-3406  0.419
2017 Lilyquist J, LaDuca H, Polley E, Shimelis H, Hu C, Moore R, Hart SN, Couch FJ, Dolinsky J, Goldgar DE. Abstract 1287: Multigene panel testing and risk estimates in 10,233 ovarian cancer cases Epidemiology. 77: 1287-1287. DOI: 10.1158/1538-7445.Am2017-1287  0.357
2016 Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Research and Treatment. PMID 28008555 DOI: 10.1007/S10549-016-4085-4  0.419
2016 Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, ... ... Shimelis H, et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 108. PMID 26586665 DOI: 10.1093/Jnci/Djv315  0.494
2016 Offit K, Schrader KA, Maxwell KN, Vijai J, Hart S, Thomas T, Wubbenhorst B, Ravichandran V, Moore R, Hu C, Lilyquist J, Shimelis H, Slavin TP, Domchek SM, Robson ME, et al. Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing. Journal of Clinical Oncology. 34: 1515-1515. DOI: 10.1200/Jco.2016.34.15_Suppl.1515  0.461
2016 Couch FJ, Akinhanmi M, Shimelis H, Hallberg EJ, Hu C, Hart S, Moore R, Meeks H, Huether R, Laduca H, Chao E, Goldgar D, Dolinsky JS. Risks of triple negative breast cancer associated with cancer predisposition gene mutations. Journal of Clinical Oncology. 34: 1513-1513. DOI: 10.1200/Jco.2016.34.15_Suppl.1513  0.476
2015 Couch FJ, Shimelis H, Schroeder A, Hu C, Hallberg E, Lipton G, Iversen E, Lindor NM. Abstract 4685: Characterization of variants of uncertain significance (VUS) in breast and ovarian cancer predisposition genes Cancer Research. 75: 4685-4685. DOI: 10.1158/1538-7445.Am2015-4685  0.474
2014 Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, Leminen A, Bützow R, Blomqvist C, Barkardottir RB, Couch FJ, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 15172-7. PMID 25288723 DOI: 10.1073/Pnas.1407909111  0.459
2013 Linn D, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, Shimelis H, Chen H, Li W, Xu K, Chen M, Qiu Y. Abstract 4089: Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. Cancer Research. 73: 4089-4089. DOI: 10.1158/1538-7445.Am2013-4089  0.725
2012 Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, Shimelis H, Chen H, Li W, Xu K, Chen M, Qiu Y. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. The Journal of Biological Chemistry. 287: 22959-68. PMID 22584579 DOI: 10.1074/Jbc.M111.338350  0.722
2011 Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. The Journal of Biological Chemistry. 286: 36152-60. PMID 21878636 DOI: 10.1074/Jbc.M111.265124  0.665
2009 Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 15: 270-82. PMID 19345326 DOI: 10.1016/J.Ccr.2009.02.021  0.719
2008 Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. The Journal of Biological Chemistry. 283: 3349-56. PMID 18056989 DOI: 10.1074/Jbc.M707773200  0.699
Show low-probability matches.